Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Nov 24;140(21):2248-2260.
doi: 10.1182/blood.2022015478.

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Mahmoud Elsawy  1 , Julio C Chavez  2 , Irit Avivi  3 , Jean-François Larouche  4 , Luciano Wannesson  5 , Kate Cwynarski  6 , Keren Osman  7 , Kelly Davison  8 , Jakob D Rudzki  9 , Saurabh Dahiya  10 , Kathleen Dorritie  11 , Samantha Jaglowski  12 , John Radford  13 , Franck Morschhauser  14 , David Cunningham  15 , Alejandro Martin Garcia-Sancho  16 , Dimitrios Tzachanis  17 , Matthew L Ulrickson  18 , Reem Karmali  19 , Natasha Kekre  20 , Catherine Thieblemont  21 , Gunilla Enblad  22 , Peter Dreger  23 , Ram Malladi  24   25 , Namita Joshi  26 , Wei-Jhih Wang  26 , Caitlyn T Solem  26 , Julia Thornton Snider  27 , Paul Cheng  27 , Christina To  27 , Marie José Kersten  28
Affiliations
Clinical Trial

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Mahmoud Elsawy et al. Blood. .

Abstract

Here, we report the first comparative analysis of patient-reported outcomes (PROs) with chimeric antigen receptor T-cell therapy vs standard-of-care (SOC) therapy in second-line relapsed/refractory large B-cell lymphoma (R/R LBCL) from the pivotal randomized phase 3 ZUMA-7 study of axicabtagene ciloleucel (axi-cel) vs SOC. PRO instruments were administered at baseline, day 50, day 100, day 150, month 9, and every 3 months from randomization until 24 months or an event-free survival event. The quality of life (QoL) analysis set comprised patients with a baseline and ≥1 follow-up PRO completion. Prespecified hypotheses for Quality of Life Questionnaire-Core 30 (QLQ-C30) physical functioning, global health status/QoL, and EQ-5D-5L visual analog scale (VAS) were tested using mixed-effects models with repeated measures. Clinically meaningful changes were defined as 10 points for QLQ-C30 and 7 for EQ-5D-5L VAS. Among 359 patients, 296 (165 axi-cel, 131 SOC) met inclusion criteria for QoL analysis. At day 100, statistically significant and clinically meaningful differences in mean change of scores from baseline were observed favoring axi-cel over SOC for QLQ-C30 global health status/QoL (estimated difference 18.1 [95% confidence interval (CI), 12.3-23.9]), physical functioning (13.1 [95% CI, 8.0-18.2]), and EQ-5D-5L VAS (13.7 [95% CI, 8.5-18.8]; P < .0001 for all). At day 150, scores significantly favored axi-cel vs SOC for global health status/QoL (9.8 [95% CI, 2.6-17.0]; P = .0124) and EQ-5D-5L VAS (11.3 [95% CI, 5.4-17.1]; P = .0004). Axi-cel showed clinically meaningful improvements in QoL over SOC. Superior clinical outcomes and favorable patient experience with axi-cel should help inform treatment choices in second-line R/R LBCL. This trial was registered at www.clinicaltrials.gov as #NCT03391466.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: M.E. reports honoraria from Kite, Bristol Myers Squibb, Novartis, Pfizer, and Janssen and consulting or advisory role with Kite, Bristol Myers Squibb, Novartis, Pfizer, and Janssen. J.C.C. reports consultancy fees for Kite, AbbVie, Janssen, ADC Therapeutics, Karyopharm, Kymera, Genmab, and Novartis; speakers' bureau participation for Morphosys, Epizyme, Bristol Myers Squibb, BeiGene, and AstraZeneca; and research funding from AstraZeneca, Merck, ADC Therapeutics, and Adaptive. I.A. reports speakers’ bureau participation for Kite and Novartis. L.W. reports consultancy or advisory role for Novartis, MSD, Bristol Myers Squibb, AstraZeneca, and Roche; research funding from Roche; and expert testimony from AstraZeneca and Novartis. K.C. reports consultancy or advisory role for Kite, Roche, Takeda, Celgene, Atara, Gilead, Janssen, and Incyte; speakers' bureau for Roche, Takeda, Kite, Gilead, and Incyte; and travel support from Roche, Takeda, Kite, Janssen, and Bristol Myers Squibb/Celgene. K.O. reports consultancy or advisory role for Kite. K. Davison reports consulting or advisory role for Merck, AstraZeneca, Janssen, Novartis, Gilead, AbbVie, and Celgene. J.D.R. reports consultancy or advisory role with Kite, Novartis, Amgen, MSD, Roche, and Bristol Myers Squibb/Celgene; speakers' bureau for Kite, Novartis, and Roche; and research funding from Kite and Novartis. S.D. reports consultancy or advisory role for Kite, Atara Biotherapeutics, and Bristol Myers Squibb and research funding from Jazz Pharmaceuticals and Miltenyi Biotech. K. Dorritie reports research funding from Kite, Juno/Bristol Myers Squibb, Hoffman-LaRoche, Janssen, and Genmab. S.J. reports consultancy or advisory role for Kite, Juno, Novartis, Takeda, and CRISPR Therapeutics and research funding from Kite and Novartis. J.R. reports stock or other ownership in ADC Therapeutics and AstraZeneca; honoraria from Takeda, ADCT, and Bristol Myers Squibb; consultancy or advisory role for Takeda, ADCT, Bristol Myers Squibb, and Novartis; speakers' bureau from Takeda and ADCT; research funding from Takeda; and expert testimony from Takeda and ADCT. F.M. reports consultancy or advisory role for Roche, Bristol Myers Squibb, Gilead, Epizyme, Genmab, Novartis, and AbbVie; speakers’ bureau from Roche; and expert testimony from Roche and Genentech. D.C. reports research funding from MedImmune, AstraZeneca, Clovis, Eli Lilly, 4SC, Bayer, Celgene, and Roche. A.M.G.-S. reports honoraria from Roche, Celgene, Janssen, Servier, and Gilead; consulting or advisory role with Roche, Bristol Myers Squibb/Celgene, Morphosys, Kyowa Kirin, Clinigen, Eusa Pharma, Novartis, Gilead, Servier, and Incyte; research funding from Janssen; expert testimony from Gilead; and travel support Roche, Celgene, Servier, and Kern Pharma. D.T. reports consultancy or advisory role for Partner, Takeda, EUSA, Kite, Kyowa Kirin, and Magenta; speakers' bureau participation for Takeda and Kite; and research funding from Bristol Myers Squibb, Kite, Genentech, Incyte, and Fate Therapeutics. R.K. reports consulting or advisory role with BeiGene, Kite, Morphosys, Karyopharm, Bristol Myers Squibb/Celgene, Genentech, Roche, Janssen, and Pharmacyclics; speakers’ bureau from AstraZeneca, BeiGene, Kite, and Morphosys; and research funding from Kite, Bristol Myers Squibb/Celgene, and Takeda. N.K. reports honoraria from Gilead, Novartis, and Celgene and consultancy or advisory role for Gilead, Novartis, and Celgene. C. Thieblemont reports honoraria from Bristol Myers Squibb/Celgene, AbbVie, Takeda, Novartis, Roche, Kite and Incyte; consultancy or advisory role for Bristol Myers Squibb/Celgene, AbbVie, Takeda, Roche, Novartis, Kite, and Incyte; and travel support from Bristol Myers Squibb/Celgene, Takeda, Roche, Novartis, and Kite. G.E. reports consultancy or advisory role with Kite and Gilead Sciences. P.D. reports consulting or advisory role for AbbVie, AstraZeneca, bluebird bio, Bristol Myers Squibb, Gilead Sciences, Janssen, and Novartis and research funding from Riemser. R.M. reports honoraria from Gilead; consultancy or advisory role Gilead Science; and travel support from Gilead. N.J., W.-J.W., and C.T.S. report employment with OPEN Health; consultancy or advisory role for Kite through employment at OPEN Health; and research funding from multiple clients through employment at OPEN Health. J.T.S. and C. To report employment with Kite and stock or other ownership in Gilead. P.C. reports employment with Kite; stock or other ownership in Gilead; and travel support from Kite. M.J.K. reports honoraria from Kite, Novartis, Miltenyi Biotech, Roche, and Bristol Myers Squibb/Celgene; consultancy or advisory role for Kite, Roche, Bristol Myers Squibb/Celgene, Novartis, and Miltenyi Biotech; research funding from Kite, Roche, Takeda, and Celgene; and travel support from Kite, Roche, Novartis, and Miltenyi Biotech. The remaining authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Mixed model with repeated measures for change from baseline for secondary PRO endpoints (QoL analysis set). Results populated only through month 15 due to lack of model convergence when using time points. Horizontal lines represent the minimally important difference thresholds for clinically meaningful change and are provided for clarity of interpretation. This model included variables for treatment, time, and treatment by time interaction (primary analysis) and controlled for response to first-line therapy (primary refractory, relapse = 6 months of first-line therapy vs relapse > 6 and = 12 months of first-line therapy) and age-adjusted IPI (0-1 vs 2-3) at time of screening. Patients who had PRO assessments after an EFS event (supplemental Results) were not censored to avoid biasing results by excluding patients with worse outcomes. ∗P < .05.
Figure 2.
Figure 2.
Mixed model with repeated measures for change from baseline for exploratory EORTC QLQ-C30 functional scales (QoL analysis set). Results populated only through month 15 due to lack of model convergence when using time points. For EORTC QLQ-C30 domains, figures are based on model 1. Horizontal lines represent the minimally important difference thresholds for clinically meaningful change and are provided for clarity of interpretation. This model included variables for treatment, time, and treatment by time interaction (primary analysis) and controlled for response to first-line therapy (primary refractory, relapse = 6 months of first-line therapy vs relapse > 6 and = 12 months of first-line therapy) and age-adjusted IPI (0-1 vs 2-3) at time of screening. Patients who had PRO assessments after an EFS event (supplemental Results) were not censored to avoid biasing results by excluding patients with worse outcomes. ∗P < .05.
Figure 3.
Figure 3.
Mixed model with repeated measures for change from baseline for exploratory EORTC QLQ-C30 symptom scales (QoL analysis set). Results populated only through month 15 due to lack of model convergence when using time points. For EORTC QLQ-C30 domains, figures based on model 1. Horizontal lines represent the minimally important difference thresholds for clinically meaningful change and are provided for clarity of interpretation. This model included variables for treatment, time, and treatment by time interaction (primary analysis) and controlled for response to first-line therapy (primary refractory, relapse = 6 months of first-line therapy vs relapse > 6 and = 12 months of first-line therapy) and age-adjusted IPI (0-1 vs 2-3) at time of screening. Patients who had PRO assessments after an EFS event (supplemental Results) were not censored to avoid biasing results by excluding patients with worse outcomes. ∗P < .05.
Figure 3.
Figure 3.
Mixed model with repeated measures for change from baseline for exploratory EORTC QLQ-C30 symptom scales (QoL analysis set). Results populated only through month 15 due to lack of model convergence when using time points. For EORTC QLQ-C30 domains, figures based on model 1. Horizontal lines represent the minimally important difference thresholds for clinically meaningful change and are provided for clarity of interpretation. This model included variables for treatment, time, and treatment by time interaction (primary analysis) and controlled for response to first-line therapy (primary refractory, relapse = 6 months of first-line therapy vs relapse > 6 and = 12 months of first-line therapy) and age-adjusted IPI (0-1 vs 2-3) at time of screening. Patients who had PRO assessments after an EFS event (supplemental Results) were not censored to avoid biasing results by excluding patients with worse outcomes. ∗P < .05.
Figure 4.
Figure 4.
Time until definitive improvement Kaplan-Meier curves for exploratory EORTC QLQ-C30 global health status/QoL, EORTC QLQ-C30 physical functioning, EQ-5D-5L VAS, and EORTC QLQ-C30 dyspnea. Cumulative incidence of improvement (greater than the minimally important difference) in scores from baseline with no further decline, controlling for death as a competing risk; an event was defined as the first time reaching the threshold for improvement and no deterioration below the threshold at later time points. Patients who had PRO assessments after an EFS event (supplemental Results) were not censored to avoid biasing results by excluding patients with worse outcomes. + on the curve, censor; CIF, cumulative incidence function; NE, not estimable.
See this image and copyright information in PMC

Comment in

References

    1. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808. [published correction appears in Blood. 2018;131(5):587–588] - PMC - PubMed
    1. Zahid U, Akbar F, Amaraneni A, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12(3):217–226. - PMC - PubMed
    1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–1545. - PubMed
    1. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190. - PMC - PubMed
    1. Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51–57. - PubMed

Publication types

MeSH terms

Associated data